Implantation of accommodating intraocular lenses for cataract

Interventional procedures guidance
Published: 28 February 2007

www.nice.org.uk/guidance/ipg209

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with
those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

1 Guidance

1.1 Current evidence suggests that there are no major safety concerns associated with the implantation of accommodating lenses for cataract. There is evidence of short-term efficacy in correcting visual acuity but there is inadequate evidence that the procedure achieves accommodation. Therefore, the procedure should not be used without special arrangements for consent and for audit or research.

1.2 Clinicians wishing to undertake implantation of accommodating lenses should take the following actions.

- Ensure that patients understand the uncertainty about the procedure's efficacy, and provide them with clear written information. In addition, use of the Institute's information for patients ('Understanding NICE guidance') is recommended.

- Audit and review clinical outcomes of all patients having implantation of accommodating lenses (see section 3.1).

1.3 Publication of long-term efficacy outcomes of the procedure will be useful, particularly on the effects on accommodation. The Institute will review the procedure in due course.

2 The procedure

2.1 Indications

2.1.1 A cataract is the opacification of the eye's natural lens. It usually develops over a period of time, causing a gradual deterioration in
eyesight, and may eventually lead to blindness.

2.1.2 Surgical treatment involves replacing the patient's opacified lens with an artificial lens, which is usually of fixed power (monofocal), requiring the use of reading spectacles for near vision. More recently, intraocular lenses have been developed that allow both distance and reading vision without glasses. These can be either multifocal lenses, which enable both near and distance vision by virtue of the design of the lens itself, or accommodating lenses, which move within the eye in a similar manner to the human lens. Cataract surgery is usually performed under local anaesthesia.

2.2 Outline of the procedure

2.2.1 An ultrasound probe is used to break the opacified lens into tiny pieces, which are removed through a small incision in the cornea (phacoemulsification). An accommodating lens rather than a standard intraocular lens is then inserted through the incision. The aim of the procedure is to allow the eye to focus on near as well as distant objects, reducing the need for spectacles.

2.3 Efficacy

2.3.1 Only one randomised trial reported that both the patient and the examiner were blind to which lens had been implanted. Two randomised controlled trials reported a statistically significant larger degree of accommodation with accommodating lenses than with monofocal lenses: 1.9 dioptres (D) versus 0 D (p < 0.05), and 1.01 D versus 0.5 D (p = 0.01).

2.3.2 Four randomised controlled trials reported significantly better distance-corrected near visual acuity for eyes with an accommodating lens than for eyes with a standard intraocular lens; follow-up ranged between 6 and 12 months. In one of these studies, the difference was statistically significant at 6 months (J9.3 versus J12.4, p = 0.004) but not at 12 months (J11.5 versus J12.8, p = 0.1), although the 12-month follow-up included only 67% (40/60) of eyes. (Note that a larger J number means less visual acuity.) In another of these studies, 66% of eyes (numbers not
2.3.3 Two Specialist Advisers considered this procedure to be a minor variation of an existing procedure. One Specialist Adviser commented that the technology is in the early stages and that more efficacious lenses are likely to be developed in the future. The mechanism of action of accommodating lenses is unclear.

2.4 Safety

2.4.1 A non-randomised comparative study reported that after 12 months' follow-up, 13% (3/24) of eyes with an accommodating lens required capsulotomy for posterior capsule opacification, compared with 25% (8/32) of eyes with a multifocal lens and 29% (7/24) of eyes with a bifocal lens (p value not reported). Two case series reported capsulotomy for posterior capsule opacification in 14% (37/263) and 18% (12/65) of eyes with an accommodating lens after mean follow-up of 12 and 23 months, respectively.

2.4.2 One randomised controlled trial of 42 eyes reported anterior and posterior capsule opacification in 86% of eyes with an accommodating lens, compared with 25% (5/20) of eyes with a traditional lens (follow-up 12 months; p value not reported). Another randomised controlled trial of 42 eyes reported mild posterior capsule opacification in 21% of eyes with an accommodating lens and 22% of eyes with a monofocal lens after 6 months' follow-up (p value not reported).

2.4.3 A randomised controlled trial reported intraoperative haemorrhage in the anterior chamber in 1 of 40 eyes (3%) with an accommodating lens. A case series reported cystoid macular oedema in 4% (12/324) of eyes with an accommodating lens over a 12-month follow-up period. Persistent cystoid macular oedema was reported in 1% (3/304) of eyes.
2.4.4 A non-randomised controlled trial reported halos in 8% (2/24) and flare, flashes or glare each in 1 of 24 eyes (4%) with an accommodating lens. Higher rates of halos, flare and glare were reported by patients with a multifocal or bifocal lens. For more details, refer to the 'Sources of evidence' section.

2.4.5 The Specialist Advisers listed potential adverse events as including lens decentration, posterior capsule opacification, lens or haptics buckling, development of capsular contraction syndrome and loss of quality of vision.

2.5 Other comments

2.5.1 It was noted that the evidence reviewed on this procedure relates to the treatment of cataract and not to the correction of presbyopia.

2.5.2 It was also noted that accommodating lenses are at a relatively early stage of development and that the technology is evolving rapidly.

3 Further information

3.1 This guidance requires that clinicians undertaking the procedure make special arrangements for audit. The Institute has identified relevant audit criteria and developed an audit tool (which is for use at local discretion).

Andrew Dillon
Chief Executive
February 2007

Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document:

'Interventional procedure overview of the implantation of accommodating intraocular lenses during cataract surgery', October 2006.
**Information for patients**

NICE has produced information describing its guidance on this procedure for patients and their carers (‘Understanding NICE guidance’). It explains the nature of the procedure and the decision made, and has been written with patient consent in mind.

### 4 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE interventional procedure guidance process.

We have produced a summary of this guidance for patients and carers. Tools to help you put the guidance into practice and information about the evidence it is based on are also available.

**Changes since publication**

17 January 2012: minor maintenance.

**Your responsibility**

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to
implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2007. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.